Corporate Profile
Entera is a leader in the development of orally delivered macromolecules, including peptides and other therapeutic proteins. The Company focuses on significant unmet medical needs where a mini daily tablet form of a peptide treatment or replacement therapy holds the potential to transform the standard of care. The Company’s most advanced product candidates, EB613 for the treatment of high risk, post-menopausal osteoporosis and EB612 for the treatment of hypoparathyroidism, are in clinical development.
INVESTOR MEDIA
Press Releases
Recent Events
- Dec 4, 2024 from 9:35 AM to 9:55 AM EST
SEC Filings
Filing Date | Description | View |
---|---|---|
|
An amendment to the SC 13G filing |
|
|
Initial filing by director officer or owner of more than ten percent |
|
|
Report of unscheduled material events or corporate event |
CORPORATE GOVERNANCE
governance-menu